S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy

Immune checkpoint blockade (ICB) is a powerful approach for cancer therapy although good responses are only observed in a fraction of cancer patients. Breast cancers caused by deficiency of breast cancer-associated gene 1 (BRCA1) do not have an improved response to the treatment. To investigate this...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianjie, Shu, Xiaodong, Xu, Jun, Su, Sek Man, Chan, Un In, Mo, Lihua, Liu, Jianlin, Zhang, Xin, Adhav, Ragini, Chen, Qiang, Wang, Yuqing, An, Tingting, Zhang, Xu, Lyu, Xueying, Li, Xiaoling, Lei, Josh Haipeng, Miao, Kai, Sun, Heng, Xing, Fuqiang, Zhang, Aiping, Deng, Chuxia, Xu, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933470/
https://www.ncbi.nlm.nih.gov/pubmed/35304461
http://dx.doi.org/10.1038/s41467-022-29151-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933470/
https://www.ncbi.nlm.nih.gov/pubmed/35304461
http://dx.doi.org/10.1038/s41467-022-29151-5

Ejemplares similares